JP2023545579A - 眼疾患の治療のための方法と薬剤 - Google Patents

眼疾患の治療のための方法と薬剤 Download PDF

Info

Publication number
JP2023545579A
JP2023545579A JP2023546368A JP2023546368A JP2023545579A JP 2023545579 A JP2023545579 A JP 2023545579A JP 2023546368 A JP2023546368 A JP 2023546368A JP 2023546368 A JP2023546368 A JP 2023546368A JP 2023545579 A JP2023545579 A JP 2023545579A
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545579A5 (https=
Inventor
ジーゲラール ブライアン
レッドリッチ ゲイリー
Original Assignee
ライン シックス バイオテクノロジー，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903624A external-priority patent/AU2020903624A0/en
Application filed by ライン シックス バイオテクノロジー，インコーポレイティド filed Critical ライン シックス バイオテクノロジー，インコーポレイティド
Publication of JP2023545579A publication Critical patent/JP2023545579A/ja
Publication of JP2023545579A5 publication Critical patent/JP2023545579A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023546368A 2020-10-07 2021-10-07 眼疾患の治療のための方法と薬剤 Pending JP2023545579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903624 2020-10-07
AU2020903624A AU2020903624A0 (en) 2020-10-07 Methods and agents for the treatment of ocular disease
PCT/AU2021/051173 WO2022073072A1 (en) 2020-10-07 2021-10-07 Methods and agents for the treatment of ocular disease

Publications (2)

Publication Number Publication Date
JP2023545579A true JP2023545579A (ja) 2023-10-30
JP2023545579A5 JP2023545579A5 (https=) 2024-10-11

Family

ID=81127099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546368A Pending JP2023545579A (ja) 2020-10-07 2021-10-07 眼疾患の治療のための方法と薬剤

Country Status (8)

Country Link
US (3) US11618782B2 (https=)
EP (1) EP4225796A4 (https=)
JP (1) JP2023545579A (https=)
KR (1) KR20230086713A (https=)
CN (1) CN116710135A (https=)
AU (1) AU2021356298A1 (https=)
IL (1) IL301762A (https=)
WO (1) WO2022073072A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540450A (ja) * 2005-05-06 2008-11-20 ザ スクリップス リサーチ インスティテュート ＣＤ１４およびＴｏｌｌ様受容体４シグナル伝達経路を介して細胞をモジュレートする組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
PT3065761T (pt) * 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
AU2014370404A1 (en) * 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
US20160038589A1 (en) * 2014-08-11 2016-02-11 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
IL309046B2 (en) * 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
KR20190059164A (ko) * 2017-11-22 2019-05-30 건국대학교 글로컬산학협력단 가용성 cd14의 당뇨황반부종 진단 및 치료 용도
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540450A (ja) * 2005-05-06 2008-11-20 ザ スクリップス リサーチ インスティテュート ＣＤ１４およびＴｏｌｌ様受容体４シグナル伝達経路を介して細胞をモジュレートする組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 52, no. 8, JPN6025034679, 2011, pages 6026 - 6034, ISSN: 0005787741 *

Also Published As

Publication number Publication date
AU2021356298A1 (en) 2023-05-04
US20220220194A1 (en) 2022-07-14
CN116710135A (zh) 2023-09-05
AU2021356298A9 (en) 2024-04-18
US20240002489A1 (en) 2024-01-04
IL301762A (en) 2023-05-01
US12258390B2 (en) 2025-03-25
KR20230086713A (ko) 2023-06-15
WO2022073072A1 (en) 2022-04-14
US11618782B2 (en) 2023-04-04
EP4225796A4 (en) 2024-11-13
US20250230228A1 (en) 2025-07-17
EP4225796A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
JP7273204B2 (ja) 眼科疾患の処置
US11912754B2 (en) VEGFR-antibody light chain fusion protein
TWI419704B (zh) 預防及治療與補體相關之眼部病症
US12258390B2 (en) Methods and agents for the treatment of ocular disease
AU2021286278A1 (en) Methods for treating ocular diseases
JP2017536414A (ja) 血管性眼疾患を処置するための方法および製剤
CN107106681B (zh) 治疗或预防中风的方法
JP2018525332A (ja) 線維性疾患を処置するための方法および組成物
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
CA2665956A1 (en) Combination treatment for ocular diseases
JP2023540382A (ja) 心筋梗塞の処置のための治療方法および治療薬
EP2536433B1 (en) Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
US20240366777A1 (en) Anti-folate receptor conjugate combination therapy with bevacizumab
KR20250021399A (ko) 안지오포이에틴-관련 단백질 7-특이적 항체 및 그의 용도
JP2020505013A (ja) ヒトｃｄ１６０を結合する結合物及びその使用
RU2776850C2 (ru) Способы лечения глазных заболеваний
KR20250093319A (ko) Il-6 길항제에 대한 반응 예측
EA049293B1 (ru) АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
NZ735964B2 (en) Antibodies Specific For TGF-Beta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260203